NovaBridge Biosciences: accounts_receivable
| Value | {"amount": 76000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2022-06-30) |
| Status | current |
| Entity | NovaBridge Biosciences |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/048d46bf-06bd-4f66-8e31-70b61437581a
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001104659-22-117101Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001778016/accounts-receivable/2022-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/048d46bf-06bd-4f66-8e31-70b61437581a
History
- supersedes {"unit": "CNY", "value": 510000, "concept": "us-gaap:AccountsReceivableNetCurrent"} (evidence 0001104659-22-117101)